24 January 2024
Oxford PharmaGenesis has contributed to the development of the new ACCORD reporting guideline to help the medical and scientific communities to improve the reporting of research involving consensus methodologies. The guideline was published in the non-profit open access journal PLOS Medicine.
After more than 2 years of hard work, Aston & Cote Summer Fete (held on 22 June) was the perfect event for Aston & Cote Community Trust to celebrate the opening of a new playground for the young children of the village.
Leading medical journals restrict access to industry-funded research, shows a study conducted by researchers at Oxford PharmaGenesis, published in BMJ Open today. This is likely to impede further research and delay patient benefit.
It’s official – Oxford PharmaGenesis is a great place to work on both sides of the Atlantic! At the end of 2018, we won the award in our US office, and today we are proud to announce that we have also received the award in the UK, with 89% of employees rating the company a…
The world-leading, independent HealthScience communications consultancy Oxford PharmaGenesis is celebrating its second Queen’s Award for Enterprise, the UK’s highest accolade for business success.
Oxford PharmaGenesis Inc., the independent, global HealthScience communications consultancy, is proud to announce that Kevin Ryder has joined their expanding US team as Vice President, Medical Services.
I was diagnosed with a 60 mm invasive lobular tumour in my left breast (estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 [HER2] negative) without lymph node involvement in June 2015. Fortunately, I found the lump myself (in between mammograms) and was able to get it detected quickly.
